[Beta blockers, fibrinogen, and atherosclerosis].
Serrano Aguilar
P G
PG
Instituto Nacional de la Salud, Tejina, La Laguna, Santa Cruz de Tenerife.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D005260:Female; D005340:Fibrinogen / Q000032:analysis / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D012307:Risk Factors; D013927:Thrombosis / Q000517:prevention & control
D000319:Adrenergic beta-Antagonists; D008074:Lipoproteins; D005340:Fibrinogen
Bloqueadores beta, fibrinógeno y aterosclerosis.